SAM
CRL icon

Shell Asset Management’s Charles River Laboratories CRL Stock Holding History

Shell Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-215
Closed -$80K – 1402
2021
Q2 		$80K Sell
215
-4,761
-96% -$1.59M ﹤0.01% 1394
2021
Q1 		$1.44M Sell
4,976
-2,685
-35% -$746K 0.03% 428
2020
Q4 		$1.91M Sell
7,661
-2,893
-27% -$689K 0.04% 390
2020
Q3 		$2.39M Sell
10,554
-3,035
-22% -$630K 0.06% 307
2020
Q2 		$2.37M Sell
13,589
-142
-1% -$22.7K 0.06% 291
2020
Q1 		$1.73M Sell
13,731
-208
-1% -$31.2K 0.05% 328
2019
Q4 		$2.13M Sell
13,939
-298
-2% -$41.3K 0.05% 350
2019
Q3 		$1.89M Sell
14,237
-124
-0.9% -$16.6K 0.04% 355
2019
Q2 		$2.04M Sell
14,361
-328
-2% -$44.5K 0.05% 350
2019
Q1 		$2.13M Hold
14,689
– – 0.05% 342
2018
Q4 		$1.66M Sell
14,689
-1,200
-8% -$150K 0.04% 360
2018
Q3 		$2.14M Sell
15,889
-5,081
-24% -$627K 0.04% 375
2018
Q2 		$2.35M Sell
20,970
-1,125
-5% -$122K 0.05% 368
2018
Q1 		$2.36M Hold
22,095
– – 0.05% 362
2017
Q4 		$2.42M Sell
22,095
-5,774
-21% -$628K 0.05% 366
2017
Q3 		$3.01M Sell
27,869
-600
-2% -$61.6K 0.07% 294
2017
Q2 		$2.88M Hold
28,469
– – 0.06% 311
2017
Q1 		$2.56M Sell
28,469
-1,994
-7% -$169K 0.06% 325
2016
Q4 		$2.32M Sell
30,463
-268
-0.9% -$20.4K 0.05% 355
2016
Q3 		$2.56M Sell
30,731
-1,406
-4% -$118K 0.05% 347
2016
Q2 		$2.65M Sell
32,137
-1,826
-5% -$150K 0.06% 317
2016
Q1 		$2.58M Sell
33,963
-2,032
-6% -$150K 0.06% 304
2015
Q4 		$2.89M Sell
35,995
-2,252
-6% -$162K 0.07% 278
2015
Q3 		$2.29M Buy
38,247
+1,784
+5% +$128K 0.04% 418
2015
Q2 		$2.56M Sell
36,463
-1,672
-4% -$124K 0.05% 350
2015
Q1 		$3.02M Sell
38,135
-112
-0.3% -$8.26K 0.05% 327
2014
Q4 		$2.43M Hold
38,247
– – 0.04% 409
2014
Q3 		$2.29M Buy
38,247
+3,571
+10% +$204K 0.04% 431
2014
Q2 		$1.86M Sell
34,676
-403
-1% -$22.1K 0.03% 525
2014
Q1 		$2.12M Buy
+35,079
New +$2.04M 0.04% 469

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Shell Asset Management's CRL Position: Q3 2021 in Review

Shell Asset Management sold out of Charles River Laboratories (CRL) in Q3 2021, closing a stake of 215 shares — an estimated $80K sold.

Shell Asset Management first reported a position in CRL in Q1 2014 and held it in 30 quarters. The position peaked at $3.02M in Q1 2015. 677 funds tracked by Wall St. Rank hold CRL as of Q3 2021.

  • Shell Asset Management reported no remaining Charles River Laboratories position as of Q3 2021 after selling out during the quarter.
  • Shell Asset Management sold 215 Charles River Laboratories shares in Q3 2021, an estimated $80K.
  • Shell Asset Management first reported a position in Charles River Laboratories in Q1 2014 and held it in 30 quarters.
  • Shell Asset Management's Charles River Laboratories position peaked at $3.02M in Q1 2015.
  • 677 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2021.

Based on Shell Asset Management's 13F filing for Q3 2021, filed 4 Nov 2021.